Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam and Isis License microRNA Patent Applications from Max Planck Society

NEW YORK, Oct. 19 (GenomeWeb News) - Alnylam Pharmaceuticals and Isis Pharmaceuticals have co-exclusively licensed RNAi patent applications from the Max Planck Society, the companies said today.

 

Under the agreement, Max Planck Society, of Germany, grants Alnylam of  Cambridge, Mass., and Isis ofCarlsbad, Calif., rights to all therapeutic uses of more than 100 naturally occurring mammalian microRNAs.

 

These microRNAs, discovered by Thomas Tuschl, a co-founder of Alnylam, could potentially become drug targets or therapeutic products, according to the companies.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.